Poor Outcomes in Poor Patients?: Peripartum Cardiomyopathy-Not Just Black and White.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually.ESC heart failure · 2021
   Review
2. Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature.ESC heart failure · 2021
   Review
3. Peripartum cardiomyopathy.Herz · 2018
   Review
4. Bromocriptine for the Treatment of Peripartum Cardiomyopathy.Cardiac failure review · 2018
   Review

Corrections and comments

• Comment on
  Comparison of Clinical Characteristics and Outcomes of Peripartum Cardiomyopathy Between African American and Non-African American Women.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as